<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001915'>Aplastic anemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> were successfully treated with an intermittent administration of high-dose 1 alpha-hydroxy-<z:chebi fb="0" ids="28940">vitamin D3</z:chebi>, an active analogue of 1,25-dihydroxyvitamin D3 </plain></SENT>
<SENT sid="1" pm="."><plain>This effect was considered to be through the differentiation-inducing and immunomodulatory actions of 1,25-dihydroxyvitamin D3 </plain></SENT>
<SENT sid="2" pm="."><plain>The only adverse effect was <z:hpo ids='HP_0002150'>hypercalciuria</z:hpo> which was controllable by decreasing the dose </plain></SENT>
</text></document>